Quantcast

Latest Oncolytic virus Stories

2014-09-02 08:30:29

First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogene laherparepvec is an...

2014-09-02 08:28:45

CALGARY, Sept. 2, 2014 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Baird 2014 Health Care Conference in a session on Wednesday September 3(rd), 2014 at 9:05 a.m. ET. The conference takes place on September 3(rd) and 4(th) at the New York Palace, in New York, NY. A live audio link to the webcast session will be available at: http://wsw.com/webcast/baird39/oncy or on the company's website at...

2014-07-10 08:27:19

SEOUL, South Korea, BUSAN, South Korea and SAN FRANCISCO, July 10, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today a publication that reviews data from the company's oncolytic immunotherapy program, including its lead product Pexa-Vec. Additionally, the publication outlines the rationale for combination therapy with other cancer immunotherapies, such as...

2014-07-08 08:29:42

CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN(®) versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section...

2014-06-23 04:20:52

Inhibits Tumor Growth and Vascular Progenitors for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumors CINCINNATI, June 23, 2014 /PRNewswire/ -- Bacterial Robotics, a synthetic microbial biotechnology firm, today announced it secured an oncolytic herpes simplex virus (oHSV) from Nationwide Children's Hospital. The oHSV expresses the human tissue inhibitor metalloproteinases (TIMP3) or firefly luciferase rQT3. The Company is developing unique therapeutic ViruBots(TM). With...

2014-06-20 08:23:15

BUSAN, South Korea and SAN FRANCISCO, June 20, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that the company will make a presentation next week at the BIO Business Forum, which is a part of the 2014 BIO International Convention being held in San Diego, CA. David McDonald, chief business officer of SillaJen, will present on Tuesday, June 24, 2014 at 2:15...

2014-06-19 16:26:16

Merger Creates Global Leader In Oncolytic Immunotherapy BUSAN, South Korea and SAN FRANCISCO, June 19, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that it has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics. SillaJen's lead product Pexa-Vec (formerly JX-594) demonstrated an overall survival...

2014-06-19 08:28:06

CALGARY, June 19, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated May 9, 2014 were elected as directors at its 2014 Annual Meeting of Shareholders, held on Wednesday June 18(th), 2014. On a vote by ballot, the following 10 nominees proposed by management were elected as Directors of Oncolytics to serve until the Company`s next Annual Meeting of Shareholders or until their...

2014-06-18 04:21:16

Unique Immuno-Oncolytic Therapy Gets Closer to a More Effective, Safer Cancer Treatment and Potential Cure CLEVELAND, June 18, 2014 /PRNewswire-USNewswire/ --­­ Western Oncolytics Ltd., a biotech company specializing in immuno-oncolytic cancer therapies, has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill...

2014-06-17 11:02:54

Ohio State University Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Viruses that are designed to kill cancer cells – oncolytic viruses – have shown promise in clinical trials for the...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related